Immunicom Makes StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”

Company praised for efforts to create “affordable and effective” novel cancer immunotherapies and promising technology platform with broad potential to “develop a multitude of products”  

SAN DIEGO, Jan 25, 2021 – Immunicom, Inc., a pioneering global biotechnology company, has been recognized as a “Top Ten Most Promising 2020 Biotech Startups” by StartUpCity Magazine, Immunicom announced today.

Immunicom, featured on the cover of StartUpCity’s December 2020 edition, beat out global competition in the broadly defined “biotech” category to earn this unique recognition.

StartUpCity considered the technology, market, business model, and leadership of each company in order to select the most “promising” in the sector.
StartUpCity hailed the potential efficacy and affordability of Immunicom’s immuno-oncology therapy, noting the company could “transcend healthcare barriers” with its novel technology designed to safely manipulate key immune system components without classic side effects typically associated with other treatments.  The magazine took special note of Immunicom’s apheresis-based medical device as a “platform”, recognizing the potential to create a “multitude of products” for a variety of diseases with a streamlined path to market compared to drugs and conventional therapies.
StartUpCity contrasted the expected affordability of Immunicom’s therapy with the increasing cost of many other emerging therapies.
“The increased efficacy of emerging treatments for deadly diseases is truly exciting,” Immunicom’s Founder and CEO, Amir Jafri said.  “Immunicom is on the crest of this exciting wave of increasingly effective treatments for these deadly diseases. I believe StartUpCity chose Immunicom as a one of the ’most promising‘ biotechs with this in mind.”
Jafri also commented on the thoroughness of StartUpCity’s coverage, which reflected an understanding of “the biochemistry as well as the business model.”
Immunicom’s StartUpCity recognition follows notable progress in the US with recognition as an FDA Breakthrough technology and clinical advancement in Europe. The article can be found at:
About Immunicom
Immunicom, Inc. creates novel immunotherapies designed to treat a variety of diseases using its breakthrough ImmunopheresisTM technology platform to improve patient access and affordability. The privately held medical technology company develops innovative, non-pharmaceutical approaches for treating cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom’s revolutionary blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, with possibly fewer side effects. Immunicom’s lead product, the LW-02 column, has received U.S. FDA Breakthrough Device designation for stage IV metastatic cancer and European regulatory clearance (CE Mark certification) for use in adults with advanced, refractory, triple negative breast cancer (TNBC). Immunopheresis is currently being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Philadelphia, PA, Houston, TX, and Krakow, Poland.